In Brief: New Warnings for Carbidopa/Levodopa Products
The Medical Letter on Drugs and Therapeutics · 27.04.2026 · 68 (1753) · 72-72
DOI: 10.58347/tml.2026.1753b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 27.04.2026.
Abstract (Originalsprache)
The FDA has required that the labels of all carbidopa/levodopa-containing products (Crexont, Dhivy, Duopa, Rytary, Sinemet, Sinemet CR, Stalevo, Vyalev) include a warning about the risk of vitamin B6 (pyridoxine) deficiency and vitamin B6 deficiency-related seizures associated with their use. The combination of carbidopa/levodopa is the most effective treatment for the motor symptoms of Parkinson's disease and recent evidence favors its early use.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). In Brief: New Warnings for Carbidopa/Levodopa Products. The Medical Letter on Drugs and Therapeutics, 68(1753), 72-72. https://doi.org/10.58347/tml.2026.1753b
Vancouver
In Brief: New Warnings for Carbidopa/Levodopa Products. The Medical Letter on Drugs and Therapeutics. 2026;68(1753):72-72. doi:10.58347/tml.2026.1753b
BibTeX
@article{euvimed2026,
title = {In Brief: New Warnings for Carbidopa/Levodopa Products},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1753},
pages = {72--72},
doi = {10.58347/tml.2026.1753b}
}
EUVIMED